Cargando…

A multi-centre prospective evaluation of THEIA™ to detect diabetic retinopathy (DR) and diabetic macular oedema (DMO) in the New Zealand screening program

PURPOSE: To validate the potential application of THEIA™ as clinical decision making assistant in a national screening program. METHODS: A total of 900 patients were recruited from either an urban large eye hospital, or a semi-rural optometrist led screening provider, as they were attending their ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaghefi, Ehsan, Yang, Song, Xie, Li, Han, David, Yap, Aaron, Schmeidel, Ole, Marshall, John, Squirrell, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219993/ https://www.ncbi.nlm.nih.gov/pubmed/36057664 http://dx.doi.org/10.1038/s41433-022-02217-w

Ejemplares similares

THEIA™ development, and testing of artificial intelligence‐based primary triage of diabetic retinopathy screening images in New Zealand
por: Vaghefi, E., et al.
Publicado: (2020)

Evaluation of the prevalence of non-diabetic eye disease detected at first screen from a single region diabetic retinopathy screening program: a cross-sectional cohort study in Auckland, New Zealand
por: Ramachandran, Nishanthan, et al.
Publicado: (2021)

Towards implementation of AI in New Zealand national diabetic screening program: Cloud-based, robust, and bespoke
por: Xie, Li, et al.
Publicado: (2020)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
por: Young, James F., et al.
Publicado: (2019)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study
por: Shimura, Masahiko, et al.
Publicado: (2020)

Automation of Macular Degeneration Classification in the AREDS Dataset, Using a Novel Neural Network Design
por: Xie, Li, et al.
Publicado: (2023)

Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
por: Amoaku, Winfried M., et al.
Publicado: (2020)

Prevalence and associated risk factors of diabetic retinopathy and macular oedema in patients recently diagnosed with type 2 diabetes
por: Graue-Hernandez, Enrique O, et al.
Publicado: (2020)

Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy without history of diabetic macular oedema
por: Foos, William F, et al.
Publicado: (2022)

Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
por: Romero-Aroca, Pedro, et al.
Publicado: (2016)

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Multimodal Retinal Image Analysis via Deep Learning for the Diagnosis of Intermediate Dry Age-Related Macular Degeneration: A Feasibility Study
por: Vaghefi, Ehsan, et al.
Publicado: (2020)

Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
por: Poku, Edith, et al.
Publicado: (2013)

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series
por: Ahmed, Muna, et al.
Publicado: (2020)

TheiaEuk: a species-agnostic bioinformatics workflow for fungal genomic characterization
por: Ambrosio, Frank J., et al.
Publicado: (2023)

Indicators of Visual Prognosis in Diabetic Macular Oedema
por: Sen, Sagnik, et al.
Publicado: (2021)

Diabetic Macular Oedema Guidelines: An Australian Perspective
por: Yuen, Yew Sen, et al.
Publicado: (2023)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study
por: Zhuang, Xuenan, et al.
Publicado: (2019)

C©đmo me qued©♭ calvo /
por: Grunberg, Arnon
Publicado: (2004)

Characterisation of progression of macular oedema in the initial stages of diabetic retinopathy: a 3-year longitudinal study
por: Lobo, Conceição, et al.
Publicado: (2022)

Proportion of people with diabetic retinopathy and macular oedema varies by ethnicity in a tertiary retinal clinic in Australia: findings from the Liverpool Eye and Diabetes Study (LEADS)
por: Liew, Gerald, et al.
Publicado: (2023)

Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
por: Wong, Yun, et al.
Publicado: (2016)

Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
por: Jukić, Anđela, et al.
Publicado: (2022)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema
por: Mateos-Olivares, Milagros, et al.
Publicado: (2021)

Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema
por: Schechet, Sidney A, et al.
Publicado: (2019)

Application of Arterial Spin Labelling in Detecting Retinal Ischemia
por: Vaghefi, Ehsan, et al.
Publicado: (2017)

Should we still be performing macular laser for non-centre involving diabetic macular oedema? Results from a UK centre
por: Scanlon, Peter H., et al.
Publicado: (2021)

Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study
por: Maredza, Mandy, et al.
Publicado: (2022)

Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy
por: Prior, Lindsay, et al.
Publicado: (2022)

Current treatments in diabetic macular oedema: systematic review and meta-analysis
por: Ford, John Alexander, et al.
Publicado: (2013)

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
por: Karttunen, Tommi, et al.
Publicado: (2019)

Examination of alternative eGFR definitions on the performance of deep learning models for detection of chronic kidney disease from fundus photographs
por: An, Songyang, et al.
Publicado: (2023)

Early DMO: a predictor of poor outcomes following cataract surgery in diabetic patients. The DICAT-II study
por: Panozzo, Giacomo, et al.
Publicado: (2021)

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2021)

Two-year visual and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2022)

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Profile of a population-based diabetic macular oedema study: the Liverpool Eye and Diabetes Study (Sydney)
por: Liew, Gerald, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o9g1f6q98erk4f2b39hm6ecpih